Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment

Expert Reviews in Molecular Medicine

Volumn 17, Issue , 2015, Pages

  Lee, Esak ^a   Pandey, Niranjan B ^a   Popel, Aleksander S ^a,b  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR7; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ANTIANGIOGENIC THERAPY; BLOOD ENDOTHELIAL CELL; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CELL INTERACTION; CELLULAR SECRETION; DIAGNOSTIC VALUE; ENDOTHELIUM CELL; HUMAN; INTRACELLULAR SIGNALING; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; LYMPHATIC ENDOTHELIAL CELL; MICROENVIRONMENT; NONHUMAN; ORGAN MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; CANCER STEM CELL; METABOLISM; NEOPLASM; PATHOLOGY;

CELLULAR MICROENVIRONMENT; ENDOTHELIAL CELLS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84927757527     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/erm.2015.2     Document Type: Review

References (151)

1. Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674
2. Spano, D. and Zollo, M. (2012) Tumor microenvironment: a main actor in the metastasis process. Clinical & Experimental Metastasis 29, 381-395
3. Langley, R.R. and Fidler, I.J. (2007) Tumor cellorgan microenvironment interactions in the pathogenesis of cancer metastasis. Endocrine Reviews 28, 297-321
4. Catalano, V. et al. (2013) Tumor and its microenvironment: a synergistic interplay. Seminars in Cancer Biology 23(6 Pt B), 522-532
5. Chen, S.T. et al. (2008) Breast tumor microenvironment: proteomics highlights the treatments targeting secretome. Journal of Proteome Research 7, 1379-1387
6. Whiteside, T.L. (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904-5912
7. Watnick R.S. (2012) The role of the tumor microenvironment in regulating angiogenesis. Cold Spring Harbor Perspectives in Medicine 2, a006676
8. Funasaka, T. and Raz, A. (2007) The role of autocrine motility factor in tumor and tumor microenvironment. Cancer and Metastasis Review 26, 725-735
9. Lin, Q. and Yun, Z. (2010) Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics. Cancer Biology & Therapy 9, 949-956
10. Gao, D. and Mittal, V. (2012) Tumor microenvironment regulates epithelialmesenchymal transitions in metastasis. Expert Review of Anticancer Therapy 12, 857-859
11. Tredan, O. et al. (2007) Drug resistance and the solid tumor microenvironment. Journal of the National Cancer Institute 99, 1441-1454
12. Polyak, K., Haviv, I. and Campbell, I.G. (2009) Co-evolution of tumor cells and their microenvironment. Trends in Genetics 25, 30-38
13. Samples, J., Willis, M. and Klauber-Demore, N. (2013) Targeting angiogenesis and the tumormicroenvironment. Surgical Oncology Clinics of North America 22, 629-639
14. Li, T. et al. (2012) Molecular regulation of lymphangiogenesis in development and tumor microenvironment. Cancer Microenvironment 5, 249-260
15. Cao, Y. (2005) Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nature Reviews Cancer 5, 735-743
16. Hirakawa, S. et al. (2003) Identification of vascular lineage-specificgenesbytranscriptionalprofilingof isolated blood vascular and lymphatic endothelial cells. American Journal of Pathology 162, 575-586
17. Volmer, M.W. et al. (2004) Tumor suppressor Smad4 mediates downregulation of the antiadhesive invasion-promotingmatricellular protein SPARC: landscaping activity of Smad4 as revealed by a 'secretome' analysis. Proteomics 4, 1324-1334
18. Butler, J.M., Kobayashi, H. and Rafii, S. (2010) Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nature Reviews Cancer 10, 138-146
19. Alitalo, K. (2011) The lymphatic vasculature in disease. Nature Medicine 17, 1371-1380
20. Bronte, V. (2009) Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. European Journal of Immunology 39, 2670-2672
21. Stearman, R.S. et al. (2008) Amacrophage gene expression signature defines a field effect in the lung tumormicroenvironment. Cancer Research 68, 34-43
22. Schoppmann, S.F. et al. (2002) Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. American Journal of Pathology 161, 947-956
23. Pollard, J.W. (2009) Trophic macrophages in development and disease. Nature Reviews Immunology 9, 259-270
24. Banchereau, J. et al. (2000) Immunobiology of dendritic cells. Annual Reviewof Immunology 18, 767-811
25. Sozzani, S. et al. (2010) Trafficking properties of plasmacytoid dendritic cells in health and disease. Trends in Immunology 31, 270-277
26. Fainaru, O. et al. (2010) Tumor growth and angiogenesis are dependent on the presence of immaturedendriticcells.FASEBJournal24,1411-1418
27. Pages, F. et al. (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29, 1093-1102
28. Galon, J., Fridman, W.H. and Pages, F. (2007) The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Research 67, 1883-1886
29. Valenti, R. et al. (2007) Tumor-released microvesicles as vehicles of immunosuppression. Cancer Research 67, 2912-2915
30. Swartz, M.A. and Lund, A.W. (2012) Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nature Reviews Cancer 12, 210-219
31. Madar, S., Goldstein, I. and Rotter, V. (2013) 'Cancer associated fibroblasts'-more than meets the eye. Trends in Molecular Medicine 19, 447-453
32. Guan, J. and Chen, J. (2013) Mesenchymal stem cells in the tumor microenvironment. Biomedical Reports 1, 517-521
33. Functional subsets of mesenchymal cell types in the tumor microenvironment. Cortez E, Roswall P, Pietras K. Semin Cancer Biol (2014). Apr; 25:3-9. doi: 10.1016/j.semcancer.2013.12.010. Epub 2014 Jan 7.
34. Straussman, R. et al. (2012) Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504
35. Crawford, Y. et al. (2009) PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15, 21-34
36. Feig, C. et al. (2013) Targeting CXCL12 from FAPexpressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America 110, 20212-20217
37. Kraman, M. et al. (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330, 827-830
38. Yu, B. et al. (2013) Stromal fibroblasts in the microenvironment of gastric carcinomas promote tumor metastasis via upregulating TAGLN expression. BMC Cell Biology 14, 17
39. Stracke M.L. and Liotta L.A. (1992) Multi-step cascade of tumor cell metastasis. In Vivo 6, 309-316
40. Sahai, E. (2007) Illuminating the metastatic process. Nature Reviews Cancer 7, 737-749
41. Fidler, I.J., Kim, S.J. and Langley, R.R. (2007) The role of the organ microenvironment in the biology and therapy of cancer metastasis. Journal of Cellular Biochemistry 101, 927-936
42. Paget, S. (1989) The distribution of secondary growths in cancer of the breast. Cancer and Metastasis Review 8, 98-101
43. Fidler, I.J. (1991) Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer and Metastasis Review 10, 229-243
44. Araki, C. (1968) Organs with low incidence of neoplasm metastasis through blood circulation. Nihon Rinsho 26, 3217-3221
45. High incidence of regional and in-transit lymph node metastasis in patients with alveolar rhabdomyosarcoma. Nishida Y, Tsukushi S, Urakawa H, Sugiura H, Nakashima H, Yamada Y, IshiguroN. Int J Clin Oncol. 2014 Jun; 19(3): 536-43. doi: 10.1007/s10147-013-0571-4. Epub 2013 Jun 4.
46. Dos Santos, L.A. et al. (2011) Incidence of lymph node and adnexal metastasis in endometrial stromal sarcoma. Gynecologic Oncology 121, 319-322
47. Hirasawa, T. et al. (2009) Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. Gastric Cancer 12, 148-152
48. Lu X. et al. (2010) In vivo dynamics and distinct functions of hypoxia in primary tumor growth and organotropic metastasis of breast cancer. Cancer Research 70, 3905-3914
49. Rigamonti, N. and De Palma, M. (2013) A role for angiopoietin-2 in organ-specific metastasis. Cell Reports 4, 621-623
50. Lorusso, G. and Ruegg, C. (2012) New insights into the mechanisms of organ-specific breast cancer metastasis. Seminars in Cancer Biology 22, 226-233
51. Nguyen, D.X., Bos, P.D. and Massague, J. (2009) Metastasis: from dissemination to organspecific colonization. Nature Reviews Cancer 9, 274-284
52. Nolan, C.P. and Abrey, L.E. (2005) Leptomeningeal metastases from leukemias and lymphomas. Cancer Treatment and Research 125, 53-69
53. Patel, V. et al. (2011) Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Research 71, 7103-7112
54. Allen, C.T. et al. (2013) Emerging insights into head and neck cancer metastasis. Head Neck 35, 1669-1678
55. Padua, D. et al. (2008) TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66-77
56. Gupta, G.P. et al. (2007) Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446, 765-770
57. Goncharova, E.A. (2013) mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects. FASEB Journal 27, 1796-1807
58. Zhang, X.H. et al. (2013) Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell 154, 1060-1073
59. Lee, E., Pandey, N.B. and Popel, A.S. (2014) Pretreatment of mice with tumor-conditioned media accelerates metastasis to lymph nodes and lungs: a new spontaneous breast cancer metastasis model. Clinical & Experimental Metastasis 31, 67-79
60. Guidi, A.J. et al. (2000) Association of angiogenesis in lymph node metastases with outcome of breast cancer. Journal of the National Cancer Institute 92, 486-492
61. Edel, M.J., Harvey, J.M. and Papadimitriou, J.M. (2000) Comparison of vascularityand angiogenesis in primary invasive mammary carcinomas and in their respective axillary lymph node metastases. Clinical & Experimental Metastasis 18, 695-702
62. Inhibition of breast cancer growth and metastasis by a biomimetic peptide. Lee E, Lee SJ, Koskimaki JE, Han Z, Pandey NB, Popel AS. (2014). Sci Rep. 2014 Nov 20;4:7139. doi: 10.1038/srep07139.
63. Hood, J.L., San, R.S. and Wickline, S.A. (2011) Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Research 71, 3792-3801
64. Peinado, H. et al. (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine 18, 883-891
65. Potente, M., Gerhardt, H. and Carmeliet, P. (2011) Basic and therapeutic aspects of angiogenesis. Cell 146, 873-887
66. Jain, R.K. (1999) Transport of molecules, particles, and cells in solid tumors. Annual Review of Biomedical Engineering 1, 241-263
67. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 285, 1182-1186
68. Ferrara, N. (2002) VEGF and the quest for tumour angiogenesis factors. Nature Reviews Cancer 2, 795-803
69. Mac Gabhann, F. et al. (2010) Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdisciplinary Reviews: System Biology and Medicine 2, 694-707
70. Sarmiento, R. et al. (2009) Antiangiogenic therapies in breast cancer. Current Opinion in Investigational Drugs 10, 1334-1345
71. Labelle, M. and Hynes, R.O. (2012) The initial hours of metastasis: the importance of cooperativehost-tumor cell interactions during hematogenous dissemination. Cancer Discovery 2, 1091-1099
72. Rashid, O.M. et al. (2013) Is tail vein injection a relevant breast cancer lung metastasis model? Journal of Thoracic Disease 5, 385-392
73. Zadnik, P. et al. (2013) A novel animal model of human breast cancer metastasis to the spine: a pilot study using intracardiac injection and luciferaseexpressing cells. Journal of Neurosurgery: Spine 18, 217-225
74. Arshad, F. et al. (2010) Blood-brain barrier integrity and breast cancer metastasis to the brain. Pathology Research International 2011, 920509
75. Metastasis: new insights into organ-specific extravasation and metastatic niches. Irmisch A, Huelsken J. Exp Cell Res. 2013 Jul 1; 319(11): 1604-10. doi: 10.1016/j.yexcr.2013.02.012. Epub 2013 Feb 21.
76. Bergers, G. and Benjamin, L.E. (2003) Tumorigenesis and the angiogenic switch. Nature Reviews Cancer 3, 401-410
77. Farnsworth, R.H. et al. (2011) A role for bone morphogenetic protein-4 in lymph node vascular remodeling and primary tumor growth. Cancer Research 71, 6547-6557
78. Lee, S.Y. et al. (2012) Changes in specialized blood vessels in lymph nodes and their role in cancer metastasis. Journal ofTranslationalMedicine 10, 206
79. Von Marschall, Z. et al. (2005) Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer. International Journal of Oncology 27, 669-679
80. Kesler, C.T. et al. (2013) Lymphatic vessels in health and disease. Wiley Interdisciplinary Reviews: System Biology and Medicine 5, 111-124
81. Mohammed, R.A. et al. (2011) Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. Modern Pathology 24, 774-785
82. Kaipainen, A. et al. (1995) Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proceedings of the National Academy of Sciences of the United States of America 92, 3566-3570
83. Banerji, S. et al. (1999) LYVE-1, a newhomologue of theCD44 glycoprotein, is a lymph-specific receptor for hyaluronan. Journal of Cell Biology 144, 789-801
84. Wigle, J.T. and Oliver, G. (1999) Prox1 function is required for the development of the murine lymphatic system. Cell 98, 769-778
85. Yuan, L. et al. (2002) Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129, 4797-4806
86. Schacht, V. et al. (2003) T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema.EMBOJournal 22, 3546-3556
87. Porter, G.J. et al. (2004) Patterns of metastatic breast carcinoma: influence of tumour histological grade. Clinical Radiology 59, 1094-1098
88. Perou, C.M. et al. (2000) Molecular portraits of human breast tumours. Nature 406, 747-752
89. Moskowitz, M. et al. (1975) Breast cancer screening. Preliminary report of 207 biopsies performed in 4, 128 volunteer screenees. Cancer 36, 2245-2250
90. Matsuo, S. (1974) Studies on the factors inducing metastasis of breast cancer to lymph node. I. Lymph flow in the thoracic wall. Acta Medica Okayama 28, 259-270
91. Lipponen, P. et al. (2001) High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. European Journal of Cancer 37, 849-856
92. Skobe, M. et al. (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Medicine 7, 192-198
93. Tammela, T. and Alitalo, K. (2010) Lymphangiogenesis: molecular mechanisms and future promise. Cell 140, 460-476
94. J Clin Oncol. 2014 May 1; 32(13): 1365-83. doi:10.1200/JCO.2013.54.1177. Epub 2014 Mar 24. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.
95. Boughey, J.C. et al. (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. Journal of American Medical Association 310, 1455-1461
96. Sleeman, J.P., Cady, B. and Pantel, K. (2012) The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications. Clinical & Experimental Metastasis 29, 737-746
97. Jain, R.K. and Padera, T.P. (2002) Prevention and treatment of lymphatic metastasis by antilymphangiogenic therapy. Journal of the National Cancer Institute 94, 785-787
98. Achen, M.G., Mann, G.B. and Stacker, S.A. (2006) Targeting lymphangiogenesis to prevent tumour metastasis. British Journals of Cancer 94, 1355-1360
99. Hirakawa, S. et al. (2007) VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 109, 1010-1017
100. Harrell, M.I., Iritani, B.M. and Ruddell, A. (2007) Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. American Journal of Pathology 170, 774-786
101. Interaction of tumor cells and lymphatic vessels in cancer progression. Alitalo A, Detmar M. Oncogene. 2012 Oct 18;31(42):4499-508. doi: 10.1038/onc.2011.602.
102. Quagliata, L. et al. (2014) Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in theMT-450 syngeneic rat breast cancermodel. Clinical & ExperimentalMetastasis 31, 351-365
103. Thomas, S.N. et al. (2014) Targeting the tumordraining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials 35, 814-824
104. Lee, E. et al. (2014) Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis. Nature Communications 5, 4715
105. Lee, E. et al. (2013) Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A. Neoplasia 15, 112-124
106. Nolan, D.J. et al. (2013) Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration. Developmental Cell 26, 204-219
107. Kobayashi, H. et al. (2010) Angiocrine factors from Akt-activated endothelial cells balance selfrenewal and differentiation of haematopoietic stem cells. Nature Cell Biology 12, 1046-1056
108. Ruggeri, Z.M. (2003) Von Willebrand factor, platelets and endothelial cell interactions. Journal of Thrombosis and Haemostasis 1, 1335-1342
109. Ding, B.S. et al. (2010) Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 468, 310-315
110. Ding, B.S. et al. (2011) Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization. Cell 147, 539-553
111. Weech, A.A., Goettsch, E. and Reeves, E.B. (1934) The flow and composition of lymph in relation to the formation of edema. Journal of Experimental Medicine 60, 63-84
112. Turner, S.G. and Barrowman, J.A. (1977) Intestinal lymph flow and lymphatic transport of protein during fat absorption. Quaterly Journal of Experimental Physiology and Cognate Medical Sciences 62, 175-180
113. Nykanen, A.I. et al. (2010) Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. Circulation 121, 1413-1422
114. Forster, R., Davalos-Misslitz, A.C. and Rot, A. (2008) CCR7 and its ligands: balancing immunity and tolerance. Nature Reviews Immunology 8, 362-371
115. Scandella, E. et al. (2004) CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood 103, 1595-1601
116. Riedl, K. et al. (2003) Overexpression of CCL-21/ secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Molecular Cancer 2, 35
117. Kataru, R.P. et al. (2011) T lymphocytes negatively regulate lymph node lymphatic vessel formation. Immunity 34, 96-107
118. Angeli, V. et al. (2006) B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 24, 203-215
119. Brantley-Sieders, D.M. et al. (2011) Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium. Cancer Research 71, 976-987
120. Hamada, J. et al. (1992) Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. British Journal of Cancer 66, 349-354
121. Sadej, R. et al. (2009) CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium. Molecular Cancer Research 7, 787-798
122. Warner, K.A. et al. (2008) Endothelial cells enhance tumorcell invasionthroughacrosstalkmediatedby CXC chemokine signaling. Neoplasia 10, 131-139
123. Stromal endothelial cells directly influence cancer progression. Franses JW, Baker AB, Chitalia VC, Edelman ER. Sci Transl Med. 2011 Jan 19;3(66):66ra5. doi: 10.1126/scitranslmed.3001542.
124. Heusschen, R. et al. (2010) MicroRNAs in the tumor endothelium: novel controls on the angioregulatory switchboard. Biochimica et Biophysica Acta 1805, 87-96
125. Buchanan, C.F. et al. (2012) Cross-talk between endothelial and breast cancer cells regulates reciprocal expression of angiogenic factors in vitro. Journal of Cellular Biochemistry 113, 1142-1151
126. Am J Physiol Cell Physiol. 2014 Jul 1; 307 (1): C14-24. doi: 10.1152/ajpcell.00043.2014. Epub 2014 Apr 16. Host endothelial S1PR1 regulation of vascular permeability modulates tumor growth
127. Campos, M.S. et al. (2012) Endothelial derived factors inhibit anoikis of head and neck cancer stem cells. Oral Oncology 48, 26-32
128. Galan-Moya, E.M. et al. (2011) Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway. EMBO Reports 12, 470-476
129. Krishnamurthy, S. et al. (2010) Endothelial cellinitiated signaling promotes the survival and selfrenewal of cancer stem cells. Cancer Research 70, 9969-9978
130. Lu, J. et al. (2013) Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 23, 171-185
131. Kimura, C. et al. (2013) Endothelium-dependent epithelial-mesenchymal transition of tumor cells: exclusiverolesoftransforminggrowthfactorbeta1and beta2. Biochimica et Biophysica Acta 1830, 4470-4481
132. Sigurdsson V. et al. (2011) Endothelial induced EMT in breast epithelial cells with stem cell properties. PLoS ONE 6, e23833
133. Kim, M. et al. (2010) CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Research 70, 10411-10421
134. Wiley, H.E. et al. (2001) Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. Journal of the National Cancer Institute 93, 1638-1643
135. Hwang, T.L. et al. (2012) CCL7 and CCL21 overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis.World Journal of Gastroenterology 18, 1249-1256
136. Zhuang, Z. et al. (2010) Altered phenotype of lymphatic endothelial cells induced by highly metastatic OTSCC cells contributed to the lymphatic metastasis of OTSCC cells. Cancer Science 101, 686-692
137. Du Y. et al. (2013) The interaction between LYVE-1 with hyaluronan on the cell surface may play a role in the diversity of adhesion to cancer cells. PLoS ONE 8, e63463
138. Paupert, J., Sounni, N.E. and Noel, A. (2011) Lymphangiogenesis in post-natal tissue remodeling: lymphatic endothelial cell connection with its environment. Molecular Aspects of Medicine 32, 146-158
139. Ding, Z. et al. (2005) Morphological study of the interaction between M21melanoma and lymphatic endothelium. Lymphology 38, 87-91
140. Kerjaschki, D. et al. (2011) Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. Journal of Clinical Investigation 121, 2000-2012
141. Iiizumi, M., Bandyopadhyay, S. and Watabe, K. (2007) Interaction of Duffy antigen receptor for chemokines and KAI1: a critical step in metastasis suppression. Cancer Research 67, 1411-1414
142. Lee, E., Pandey, N.B. and Popel, A.S. (2014) Lymphatic endothelial cells support tumor growth in breast cancer. Scientific Reports 4, 5853
143. Swartz, M.A. et al. (2012) Tumormicroenvironment complexity: emerging roles in cancer therapy. Cancer Research 72, 2473-2480
144. Zheng, R. et al. (2007) Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy. Cancer Treatment and Research 135, 223-237
145. Cascone, T. et al. (2011) Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. Journal of Clinical Investigation 121, 1313-1328
146. Jain, R.K. et al. (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nature Reviews Clinical Oncology 6, 327-338
147. Kerbel, R.S. (2011) Reappraising antiangiogenic therapy for breast cancer. Breast 20(Suppl 3), S56-S60
148. Xu L. et al. (2014) Sci Transl Med. 2014 Jun 25; 6(242): 242ra84. doi: 10.1126/scitranslmed.3008455.
149. COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Science Translational Medicine 6, 242
150. Lee, E. et al. (2011) Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation. International Journal of Biochemistry & Cell Biology 43, 1812-1821
151. Koskimaki, J.E. et al. (2013) Synergy between a collagen IV mimetic peptide and a somatotropindomain derived peptide as angiogenesis and lymphangiogenesis inhibitors. Angiogenesis 16, 159-170